Almirall Predicts Plenty More Growth In Psoriasis

The Spanish group has upped its peak sales guidance for Ilumetri to €300m and believes the arrival of Stelara biosimilars will take a while to have much of an impact on the originator IL-23 class.

Almirall
• Source: Almirall

More from Earnings

More from Therapy Areas